Management

A. J. Kazimi
Chief Executive Officer

Mr. Kazimi founded Cumberland Pharmaceuticals in 1999 and has served as Chief Executive Officer and Chairman of the Board of Directors since its inception. Prior to forming Cumberland, he served as President and Chief Operating Officer of Therapeutic Antibodies Inc., a biopharmaceutical company. During his 11 years with the company, Mr. Kazimi oversaw operations in three countries and played a key role in the company’s product development strategies, licensing and distribution agreements, and the raising of more than $100 million through equity and debt financings, as well as its initial public offering. Earlier in his career, he worked at Brown-Forman Corporation, rising through a series of management positions. Mr. Kazimi currently serves on the board of directors for the Nashville Health Care Council, an industry association representing the largest concentration of healthcare companies in the United States and has served on the board for Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies, Inc. (CET). He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt Owen Graduate School of Management.

.


Martin E. Cearnal
Executive Vice President & Chief Commercial Officer

Prior to joining Cumberland as Senior Vice President of Commercial Development in 2008, Mr. Cearnal served as President and Chief Executive Officer of Physicians World. During his 15-year tenure, the company became the largest provider of continuing medical education before its acquisition by Thomson Healthcare in 2000. He served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. During his more than 44 years in the healthcare industry, Mr. Cearnal has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox®, and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles, culminating in his position as Vice President, Marketing for International Operations. Mr. Cearnal has also served on Cumberland’s Board of Directors since 2004. He is a graduate of Southeast Missouri State University.


Leo Pavliv, R.Ph.
Executive Vice President, Operations & Chief Development Officer

As Executive Vice President of Operations & Chief Development Officer, Mr. Pavliv is responsible for Cumberland’s overall drug development, including manufacturing and quality operations. Prior to joining Cumberland in 2003, he spent six years at Cato Research, a contract research organization where he served in a variety of positions, including Vice President of Pharmaceutical Development. Previously, he held scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis, Agouron Pharmaceuticals, ProCyte, and Interferon Sciences. He is a registered pharmacist (R.Ph.)


James L. Herman
Senior Vice President, National Accounts & Chief Compliance Officer

As Senior Vice President of National Accounts, Mr. Herman handles all national sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He also oversees corporate compliance efforts. Previously, he was with Solvay Pharmaceuticals where he served as Director of Managed Care, as well as Director of Trade Affairs and Customer Service. Earlier in his career, Mr. Herman spent eight years with Schwarz Pharma, where he held national sales leadership positions. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.


Todd Anthony
Senior Director, Organizational Development

Mr. Anthony joined our company in 2010 as Director, Sales Training & Development.  He is responsible for all training activities related to product knowledge and selling skills for our Sales Organization.  He began his pharmaceutical career with Berlex Laboratories Inc. in 1991 and spent 19 years at that company which is now Bayer HealthCare Pharmaceuticals following the 2006 acquisition of Schering AG.  While there he held positions of increasing responsibility including roles in Sales, Sales Training, Sales Management and Corporate Management/Leadership development.  He has a BSN degree from D’Youville College in Buffalo, NY.


Michael Bonner
Senior Director Finance & Accounting and Chief Financial Officer

Michael Bonner joined Cumberland Pharmaceuticals Inc. as Director, Financial and Tax Reporting during 2013 and directs the preparation and filing of all SEC communications along with the identification and research of technical accounting issues. He directs all Sarbanes-Oxley compliance activities including the primary interaction with internal and external auditors and directs all tax activities and tax services with external tax professionals. He has 13 years of experience in financial management, accounting and reporting, primarily within the health care industry. Prior to joining Cumberland, Mr. Bonner worked for over six years with Advocat Inc., a NASDAQ listed skilled nursing services provider, as Vice President of Accounting and Financial Reporting. Prior to that, Mr. Bonner served in a financial reporting role at LifePoint Hospitals Inc., a NASDAQ listed acute care hospital company, and spent close to five years in the assurance practice at Ernst & Young. A Certified Public Accountant, Mr. Bonner holds both a Bachelor of Science in Accounting and a Masters of Business Administration from Troy University.


Tan Cheow Choon
Senior Director, International Business
Kelly A. Menzel
Senior Director, National Hospital Sales

Ms. Menzel joined our company to launch Acetadote as a Regional Hospital Sales Representative in the Mid-Atlantic in 2004.  In addition to launching Acetadote, she acted as the Field Based Trainer and was then promoted to the Eastern District Regional Manager position in 2006. Ms. Menzel was named as Director of Hospital Sales in 2009, at the launch of Caldolor. She is responsible for all sales activities associated with Acetadote and Caldolor for the hospital division, which is comprised of 62 sales representatives and 7 District Managers throughout the country. Prior to working for Cumberland, Ms. Menzel was a Hospital Sales Representative for Roche Laboratories, selling injectable antibiotics and other injectable products to the hospital market. Previous to her entry into pharmaceuticals, Ms. Menzel held various management positions in the sales, hospitality, and banking industries, spanning 15 years. She has a Bachelor of Science degree from Towson University in Towson, Maryland.


Cindy Patton
Senior Director, Field Sales & Marketing

Since her arrival at Cumberland in January 2009, Mrs. Patton has been responsible for the Kristalose® marketing strategy and tactics, as well as providing sales direction to the Field Sales Force.  Mrs. Patton began her industry career as a Ciba Geigy sales representative in 1983. Relocating to the Ciba Geigy corporate office in 1991, she served in the Customer Marketing Group, becoming the Director of Institutional Marketing in 1995.  Following the merger that created Novartis, she held positions which included Lotensin Product Director and Ciba Novartis Sales Director for the New York Region. She graduated magna cum laude from Lambuth College with a B.B.A.


Barry L. Lee
Director, Hospital Products

In his role as Product Director, Mr. Lee is responsible for all marketing activities associated with the commercialization of Caldolor®, the company’s intravenous formulation of ibuprofen. Prior to joining the company in 2008, he spent 24 years with Bayer Healthcare Pharmaceuticals, Inc. There he held a variety of pharmaceutical sales and marketing positions and, most notably, was responsible for the launch of Yasmin® in 2001—one of the most successful industry product launches at that time. He earned a B.S. degree from Texas A&M University.